Mesoblast Limited (MESO) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Mesoblast Limited (MESO) Bundle
Engineered for accuracy, our (MESO) DCF Calculator empowers you to evaluate Mesoblast Limited's valuation using real-world financial data, offering complete flexibility to modify all key parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 32.2 | 7.5 | 10.2 | 7.5 | 5.9 | 4.6 | 3.6 | 2.8 | 2.2 | 1.7 |
Revenue Growth, % | 0 | -76.81 | 36.95 | -26.54 | -21.32 | -21.93 | -21.93 | -21.93 | -21.93 | -21.93 |
EBITDA | -75.4 | -107.6 | -76.6 | -58.6 | -62.8 | -4.6 | -3.6 | -2.8 | -2.2 | -1.7 |
EBITDA, % | -234.5 | -1443.17 | -749.91 | -780.56 | -1064.44 | -100 | -100 | -100 | -100 | -100 |
Depreciation | 3.7 | 4.3 | 4.4 | 4.1 | 4.7 | 2.3 | 1.8 | 1.4 | 1.1 | .8 |
Depreciation, % | 11.4 | 57.19 | 42.89 | 54.75 | 79.06 | 49.06 | 49.06 | 49.06 | 49.06 | 49.06 |
EBIT | -79.1 | -111.9 | -81.0 | -62.7 | -67.5 | -4.6 | -3.6 | -2.8 | -2.2 | -1.7 |
EBIT, % | -245.9 | -1500.36 | -792.8 | -835.32 | -1143.49 | -100 | -100 | -100 | -100 | -100 |
Total Cash | 129.3 | 136.9 | 60.0 | 70.9 | 62.6 | 4.6 | 3.6 | 2.8 | 2.2 | 1.7 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 1.3 | 4.6 | 4.4 | 2.3 | 21.0 | 2.2 | 1.7 | 1.3 | 1.0 | .8 |
Account Receivables, % | 4.11 | 61.56 | 43.12 | 30.34 | 355 | 47.83 | 47.83 | 47.83 | 47.83 | 47.83 |
Inventories | -.3 | -.3 | .0 | -4.3 | .0 | -.6 | -.4 | -.3 | -.3 | -.2 |
Inventories, % | -0.78368 | -3.38 | 0 | -57.65 | 0 | -12.36 | -12.36 | -12.36 | -12.36 | -12.36 |
Accounts Payable | 25.0 | 19.6 | 23.1 | 20.1 | 7.1 | 4.4 | 3.4 | 2.7 | 2.1 | 1.6 |
Accounts Payable, % | 77.66 | 262.85 | 226.02 | 268.56 | 119.79 | 95.53 | 95.53 | 95.53 | 95.53 | 95.53 |
Capital Expenditure | -2.2 | -1.6 | -.2 | -.3 | -.3 | -.4 | -.3 | -.2 | -.2 | -.1 |
Capital Expenditure, % | -6.98 | -22.09 | -2.27 | -4.19 | -4.59 | -8.02 | -8.02 | -8.02 | -8.02 | -8.02 |
Tax Rate, % | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 |
EBITAT | -70.5 | -110.9 | -80.7 | -62.5 | -67.3 | -4.5 | -3.5 | -2.7 | -2.1 | -1.7 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -45.2 | -117.0 | -73.2 | -55.2 | -99.0 | 14.0 | -2.6 | -2.1 | -1.6 | -1.3 |
WACC, % | 15.49 | 15.51 | 15.51 | 15.51 | 15.51 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 |
PV UFCF | ||||||||||
SUM PV UFCF | 7.3 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -1 | |||||||||
Terminal Value | -9 | |||||||||
Present Terminal Value | -5 | |||||||||
Enterprise Value | 3 | |||||||||
Net Debt | 56 | |||||||||
Equity Value | -54 | |||||||||
Diluted Shares Outstanding, MM | 987 | |||||||||
Equity Value Per Share | -0.05 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real MESO financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Mesoblast’s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Customizable Forecast Inputs: Adjust essential factors such as revenue projections, EBITDA margins, and capital investments.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other relevant metrics.
- High-Precision Accuracy: Leverages Mesoblast Limited's (MESO) actual financial data for credible valuation results.
- Simplified Scenario Analysis: Easily evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- 1. Open the Template: Download and open the Excel file containing Mesoblast Limited’s (MESO) preloaded data.
- 2. Edit Assumptions: Modify key inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV.
- 4. Test Scenarios: Evaluate multiple forecasts to explore various valuation outcomes.
- 5. Use with Confidence: Present professional valuation insights to enhance your decision-making.
Why Choose This Calculator for Mesoblast Limited (MESO)?
- Accurate Data: Utilize real Mesoblast financials for dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Pre-configured calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Mesoblast Limited (MESO) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Mesoblast Limited (MESO).
- Consultants: Deliver professional valuation insights on Mesoblast Limited (MESO) to clients quickly and accurately.
- Business Owners: Understand how companies like Mesoblast Limited (MESO) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Mesoblast Limited (MESO).
What the Template Contains
- Historical Data: Includes Mesoblast Limited’s (MESO) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Mesoblast Limited’s (MESO) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Mesoblast Limited’s (MESO) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.